ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Imago BioSciences Completes Enrollment in IMG-7289 Study
americanpharmaceuticalreview
August 22, 2018Imago BioSciences announced the Phase 1/2a clinical trial of?IMG-7289?for the treatment of high-risk acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) has fully enrolled at 45 patients.
Pharma Sources Insight January 2025
